Ken Griffin Trevi Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.58 - $3.51 $11,610 - $15,794
4,500 New
4,500 $15,000
Q1 2024

May 15, 2024
SELL
$1.3 - $3.7 $3,120 - $8,880
-2,400 Reduced 80.0%
600 $2,000
Q4 2023

Feb 14, 2024
BUY
$1.06 - $2.05 $3,180 - $6,149
3,000 New
3,000 $4,000
Q1 2023

May 15, 2023
BUY
$1.69 - $2.97 $60,840 - $106,920
36,000 Added 315.79%
47,400 $87,000
Q4 2022

Feb 14, 2023
BUY
$1.61 - $2.42 $18,354 - $27,588
11,400 New
11,400 $22,000

Others Institutions Holding TRVI

# of Institutions
94
Shares Held
57.1M
Call Options Held
136K
Put Options Held
5.4K
View Full List

About Trevi Therapeutics, Inc.

TRVI Quotes by TradingView
  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $169M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email